Quick Answer
BioAge Labs, Inc. reported Stockholders Equity of $272.05 million for the year ending 2025.
- BioAge Labs, Inc. showed a decrease of -15.8% in Stockholders Equity from 2024 to 2025.
- This data is from BioAge Labs, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$122.92 million | Q2 2023: -$139.31 million | Q3 2023: -$153.14 million | Q1 2024: -$185.51 million | Q2 2024: -$197.13 million | Q3 2024: $313.75 million | Q1 2025: $313.17 million | Q2 2025: $294.78 million | Q3 2025: $277.46 million.
- Over the full 4 years of available data (2022 to 2025), BioAge Labs, Inc.'s Stockholders Equity has grown by 341.7%.
- Historical annual values: Fiscal year 2025: $272.05 million | Fiscal year 2024: $323.13 million | Fiscal year 2023: -$173.40 million | Fiscal year 2022: -$112.56 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: